Anzeige
Mehr »
Login
Mittwoch, 14.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Transformation! Zweistellige Millionenvereinbarung besiegelt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6WM ISIN: KYG6096M1069 Ticker-Symbol: A1V 
Frankfurt
13.04.21
09:16 Uhr
2,300 Euro
-0,060
-2,54 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
APTORUM GROUP LIMITED Chart 1 Jahr
5-Tage-Chart
APTORUM GROUP LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
2,2202,42013.04.

Aktuelle News zur APTORUM GROUP Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
31.03.Aptorum ALS-4 Study Starts Dosing In Healthy Volunteers-
26.03.Aptorum Group Ltd - 6-K, Report of foreign issuer-
25.01.Aptorum Group Ltd - 6-K, Report of foreign issuer-
APTORUM GROUP Aktie jetzt für 0€ handeln
20.01.APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News5
20.01.Stock Alert: Aptorum Up 30% On Clearance To Initiate Phase 1 Trial Of ALS-4 In Canada 1
20.01.HotStocks USA: APTORUM, GRITSTONE und SPI ENERGY stark gehandelt18
20.01.Aptorum shares jump as Canada approves early-stage infection drug trial-
20.01.The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study9
20.01.Aptorum Group Ltd - 6-K, Report of foreign issuer3
20.01.Aptorum Group Limited: Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)254Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced...
► Artikel lesen
10.12.20Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders375Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the "Company", "Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the...
► Artikel lesen
10.12.20Aptorum Group Ltd - 6-K, Report of foreign issuer3
29.10.20Is Aptorum Group the Best Buy Among Its Peers?8
26.10.20Don't Get Swept Up In the Unproven Promise of Aptorum Group5
22.10.20Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy5
20.10.20Aptorum Group Is Risky, Despite Popularity7
16.10.20Aptorum Group Ltd - 6-K, Report of foreign issuer3
16.10.20Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020332Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the "Company", "Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the...
► Artikel lesen
02.10.20Aptorum Group Limited: Aptorum Group Announces Closing of $9.0 Million Public Offering465Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today...
► Artikel lesen
30.09.20Aptorum Group Limited: Aptorum Group Announces Pricing of $9.0 Million Public Offering544Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious...
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1